University of Maryland School of Medicine  
PKD Core Center
Antibody Validation/Vector Core Mouse Models BioBank Core
Cell Culture Cell Engineering Core Clinical Translational Core

•  Application Information

The Goals of the Pilot & Feasibility (P&F) Program are to enable eligible investigators to embark on innovative lines of inquiry related to PKD, and to recruit new expertise to the study of PKD. We anticipate that these pilot funds will allow investigators to generate sufficient data to pursue the concept through other funding mechanisms (e.g., NIH R01 grant).

The proposed project must related to the study of Polycystic Kidney Disease. The maximum grant amount is $50,000 direct costs for the one-year grant period. No more than 10% effort (1.2 Cal months) may be used to support the principal investigator's (PI) salary and fringes. You must budget funds for travel and presentation at the annual Baltimore PKD Symposium held in Baltimore, Maryland. No funding is allowed for indirect costs.

Recipients are eligible to apply for a second year of funding but renewal will be competitive and will be evaluated on the progress made during the first year of funding. A PI may receive a maximum of two years of funding.

Three groups of investigators are encouraged to apply:

1. New investigators who have never held extramural NIH support other than a K or R03 award and have not been PIs on R, P or U grants (or the equivalent) are the preferred group for funding. Those with MD, PhD or MD/PhD are eligible, will generally be junior faculty who are being mentored for independence.

2. Established investigators who are newly attracted to study PKD related projects.

3. PKD investigators who are starting a new, innovative project that represents a significant departure from their ongoing, funded research.

The order above (1-2-3) represents the priority for selecting projects for funding. Funding is for one year, with consideration for a second year upon submission of a formal application, which must include a progress report.

For dates for our Year 8 Pilot & Feasibility Program and more information about applying: Click Here

Current Projects:

Meyeon Park, M.D., M.A.S
"Novel Strategies for Cardiovascular Risk Reduction in Adults with PKD"

Tengis Pavlov, Ph.D.
"Role of P2X Signaling in the Development of PKD"

Shoshana Weiner, M.D., M.P.H.
"Use of an Interactive Text Messaging System to Promote Water Intake in Autosomal Dominant Polycystic Kidney Disease"

Projects Funded in Year 6:

Andrew Holland, M.A., Ph.D
"Genetic Modulation of Centriole Number and its Impact on Kidney Signaling and Function"

Daniel Judge, M.D.
"Cardiac Response to Gene Mutations Affecting the Primary Cilium"

Projects Funded in Year 5:

Kenneth Hallows, M.D., Ph.D.
"Effects of Metformin on the AMPK Pathway and Metabolic Biomarkers in ADPKD Kidney Epithelial Cells"

Owen Woodward, Ph.D.
"Mechanisms of Fluid Secretion and Cystic Expansion in New ADPKD Kidney Organoid 3D Model"

Kyung Lee, Ph.D.
“Inhibition of Intergrin β1 Protects Against the Development and Progression of ADPKD”

Funded Projects in Year 4:

Richard Bouley, Ph.D.
"Vasopressin Receptor Type 2 Intracellular Trafficking and Signaling in PKD"

Tianqing Kong, M.D.
"Ga12 Activation Disrupts Renal Epithelial Cell-Cell Integrity in ADPKD"

Leon McClean, MD, MPH
"Polycystins in Intestinal Mucosal Homeostatsis and Development of Murine Colitis"

Norann Zaghloul, Ph.D.
"Notch Signaling in Renal Ciliopathies"

Funded Projects in Year 3:

Andrew Ewald, Ph.D.
"Real-Time Analysis of PKD1 and PKD2 Dependent Cyst Formation"

Steven Kleene, Ph.D.
"Electrical Signaling of Wildtype and Mutated Human Polycystin-2 Channels in a Primary Cilium"

Funded Projects in Years 1 and 2:

Andrew Ewald, Ph.D.
“PKD1 and Mammary Branching Morphogenesis.”

Duojia Pan, Ph.D.
“Exploring the Role of Hippo Signaling in PKD Pathogenesis.”

Raquel Greer Charles, M.D.
"Perceived Risks and Willingness to Participate in Clinical Research of Autosomal Dominant Polycystic Kidney Disease among Ethnic/Racial Minorities."

Takanari Inoue, Ph.D.
“Quantitative Chemical Biology Approach for Characterization of Polycystin 1 and 2 in Renal Tubulogenesis.”

Subroto Chatterjee, Ph.D.
"Testing a Novel Glycolipid Inhibitor for Treatment of PKD using an Orthologous Mouse Model."

Eduational Programs Pilot & Feasibility Program

The University of Maryland Medical Center and the Division of Nephrology provide multidisciplinary care for patients with PKD. For Appointments call 410-328-5720 and ask for Karleen Schuhart. Make an appointment.

Copyright © 2013 Baltimore PKD Core Center. All Rights Reserved. Site designed by Academic Web Pages.